220 related articles for article (PubMed ID: 24475247)
21. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
[TBL] [Abstract][Full Text] [Related]
22. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.
Park G; Kim TH; Lee HO; Lim JA; Won JK; Min HS; Lee KE; Park DJ; Park YJ; Park WY
Endocr Relat Cancer; 2015 Feb; 22(1):55-63. PubMed ID: 25527510
[TBL] [Abstract][Full Text] [Related]
23. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
[TBL] [Abstract][Full Text] [Related]
24. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
25. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
28. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
29. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
[TBL] [Abstract][Full Text] [Related]
31. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
Ren S; Hirsch FR; Varella-Garcia M; Aisner DL; Boyle T; Zhou C; Camidge DR
J Thorac Oncol; 2014 Mar; 9(3):e21-3. PubMed ID: 24518095
[No Abstract] [Full Text] [Related]
32. Detection of an
Lai AZ; Schrock AB; Erlich RL; Ross JS; Miller VA; Yakirevich E; Ali SM; Braiteh F
Oncologist; 2017 Jul; 22(7):774-779. PubMed ID: 28507204
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Katayama R; Shaw AT; Khan TM; Mino-Kenudson M; Solomon BJ; Halmos B; Jessop NA; Wain JC; Yeo AT; Benes C; Drew L; Saeh JC; Crosby K; Sequist LV; Iafrate AJ; Engelman JA
Sci Transl Med; 2012 Feb; 4(120):120ra17. PubMed ID: 22277784
[TBL] [Abstract][Full Text] [Related]
34. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
[TBL] [Abstract][Full Text] [Related]
35. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
36. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
37.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract][Full Text] [Related]
38. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
[TBL] [Abstract][Full Text] [Related]
39. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
40. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
